Biological Therapy in IBD—Is There Any Optimal End Point?


Biological therapy has been used in the treatment of inflammatory bowel disease (IBD-Crohn’s disease [CD], ulcerative colitis [UC]) for more than a decade. Although guidelines exist on how to start and adjust biological therapy, information on when and how it should be stopped is still scarce. In this review, our aim is to summarize the results of the recently published papers on the outcome of the discontinuation of biological therapy in patients with CD and UC.

Share and Cite:

Farkas, K. and Molnár, T. (2014) Biological Therapy in IBD—Is There Any Optimal End Point?. Health, 6, 1296-1299. doi: 10.4236/health.2014.611158.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Schnitzler, F., Fidder, H., Ferrante, M., Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2009) Long-Term Outcome of Treatment with Infliximab in 614 Patients with Crohn’s Disease: Results from a Single-Centre Cohort. Gut, 58, 492-500.
[2] Waugh, A.W., Garg, S., Matic, K., Gramlich, L., Wong, C., Sadowski, D.C., Millan, M., Bailey, R., Todoruk, D., Cherry, R., Teshima, C.W., Dieleman, L. and Fedorak, R.N. (2010) Maintenance of Clinical Benefit in Crohn’s Disease Patients after Discontinuation of Infliximab: Long-Term Follow-Up of a Single Centre Cohort. Alimentary Pharmacology & Therapeutics, 32, 1129-1134.
[3] D’Haens, G.R., Panaccione, R., Higgins, P.D., Vermeire, S., Gassull, M., Chowers, Y., Hanauer, S.B., Herfarth, H., Hommes, D.W., Kamm, M., Löfberg, R., Quary, A., Sands, B., Sood, A., Watermeyer, G., Lashner, B., Lémann, M., Plevy, S., Reinisch, W., Schreiber, S., Siegel, C., Targan, S., Watanabe, M., Feagan, B., Sandborn, W.J., Colombel, J.F. and Travis, S. (2011) The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? The American Journal of Gastroenterology, 106, 199-212.
[4] Louis, E., Mary, J.Y., Vernier-Massouille, G., Grimaud, J.C., Bouhnik, Y., Laharie, D., Dupas, J.L., Pillant, H., Picon, L., Veyrac, M., Flamant, M., Savoye, G., Jian, R., Devos, M., Porcher, R., Paintaud, G., Piver, E., Colombel, J.F., Lemann, M. and Groupe D’etudes Thérapeutiques Des Affections Inflammatoires Digestives (2012) Maintenance of Remission among Patients with Crohn’s Disease on Antimetabolite Therapy after Infliximab Therapy Is Stopped. Gastroenterology, 1, 63-70.
[5] Steenholdt, C., Molazahi, A., Ainrworth, M.A., Brynskov, J., Østergaard Thomsen, O. and Seidelin, J.B. (2012) Outcome after Discontinuation of Infliximab in Patients with Inflammatory Bowel Disease in Clinical Remission: An Observational Danish Single Center Study. Scandinavian Journal of Gastroenterology, 47, 518-527.
[6] Armuzzi, A., Marzo, M., Felice, C., et al. (2010) Long-Term Scheduled Therapy with Infliximabin Inflammatory Bowel Disease: A Single-Centre Observational Study. Gastroenterology, 5, S691-692.
[7] Molnár, T., Lakatos, P.L., Farkas, K., Nagy, F., Szepes, Z., Miheller, P., Horváth, G., Papp, M., Palatka, K., Nyári, T., Bálint, A., Lorinczy, K. and Wittmann, T. (2013) Predictors of Relapse in Patients with Crohn’s Disease in Remission after 1 Year of Biological Therapy. Alimentary Pharmacology & Therapeutics, 37, 225-233.
[8] Farkas, K., Lakatos, P.L., Nagy, F., Szepes, Z., Miheller, P., Papp, M., Palatka, K., Bálint, A., Bor, R., Wittmann, T. and Molnár, T. (2013) Predictors of Relapse in Patients with Ulcerative Colitis in Remission after One-Year of Infliximab Therapy. Scandinavian Journal of Gastroenterology, 48, 1394-1398.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.